Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis

Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent. The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis…

Read More

Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation

Health advocate network Solace Health gained unicorn status after closing a $130 million Series C funding round. The startup’s advocates help with tasks like scheduling appointments, finding in-network providers, understanding insurance coverage and bills, and coordinating care across multiple clinicians. And they actually handle much of the work on a patient’s behalf, rather than simply…

Read More

Examining the Potential Impact of Medicare’s New WISeR Model

On January 1, 2026, the Center for Medicare & Medicaid Innovation (CMMI) launched the Wasteful and Inappropriate Service Reduction (WISeR) Model that establishes new prior authorization requirements in traditional Medicare. This analysis explores the potential impact of the WISeR model by examining recent spending and utilization trends in traditional Medicare for services selected for prior…

Read More